About
Dr. Aradhana Sarin, M.D. is Executive Director at AstraZeneca PLC since August 1, 2021 and had been its Chief Financial Officer since August 1, 2021 until February 17, 2023. She serves as Independent Director at Anheuser-Busch InBev SA/NV since April 26, 2023. She has been President and Director at Portola Pharmaceuticals, Inc. since July 02, 2020. Dr. Sarin serves as Director and President of Achillion Pharmaceuticals, Inc since January 28, 2020. Dr. Sarin had been Executive Vice President at Alexion Pharmaceuticals, Inc. since February 2019 and had also been its Chief Financial Officer since October 2019. In this role, she is responsible for overseeing global financial management, treasury, internal audit, corporate strategy, business development, Investor Relations, security activities, and business operations, including corporate planning, at Alexion.
Dr. Sarin served as Chief Strategy & Business Officer at Alexion Pharmaceuticals, Inc. since February 2019 until October 2019. Dr. Sarin joining Alexion in November 13, 2017, Dr. Sarin has served as Senior Vice President, Business Development and Corporate Strategy. Dr. Sarin served as a Director at OraSure Technologies, Inc. since February 2, 2018 until May 19, 2020. Dr. Sarin is Senior Vice President and Head of Corporate Business Development & Strategy for Alexion Pharmaceuticals since November 2017. Dr. Sarin also serves as Co-Chair of the Executive Management Committee overseeing Science and Innovation at Alexion. Dr. Sarin brings professional experience at global financial institutions. She has extensive knowledge of global healthcare systems, and has closed over 100 M&A, equity and debt financing transactions. Prior to Alexion, D
r. Sarin was at Citi Global Banking (which she joined in 2010), where she served as the Managing Director of Healthcare Corporate & Investment Banking, focusing on clients in the diagnostics, life sciences and biopharmaceutical sectors. Prior to joining Citi, Dr. Sarin served as Managing Director of Healthcare Investment Banking at UBS, where she led a number of complex M&A deals. Prior to this, Dr. Sarin worked at JP Morgan in the M&A Advisory and Healthcare groups focusing on transaction execution. Dr. Sarin held various positions in the investment banking industry. Before her banking career, Dr. Sarin spent as a medical resident doctor practicing in both India and Africa. Dr. Sarin has a strong orientation for science, an excellent understanding of the entire healthcare sector, extensive relationships, and deep transactional experience. Dr. Sarin received her MBA from Stanford Business School and obtained her medical training (M.B.B.S.) from the University of Delhi.
Personal Details
Qualifications & Experience
Other directorships (state)
(only entities turnover at least $5m p/a)
Working history
Committee/s
| Company | Committee | Role | Appointment Date | Resignation Date |
|---|---|---|---|---|
| AstraZeneca PLC | Board | Member | 01/08/2021 | |
| AB InBev | Board | Member | 01/01/2023 |